Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.

Rose A, von Spee-Mayer C, Kloke L, Wu K, Kühl A, Enghard P, Burmester GR, Riemekasten G, Humrich JY.

Cells. 2019 Oct 11;8(10). pii: E1234. doi: 10.3390/cells8101234.

2.

Evaluation of choroidal substructure perfusion in patients affected by systemic sclerosis: an optical coherence tomography angiography study.

Ranjbar M, Rothe M, Klapa S, Lange T, Prasuhn M, Grisanti S, Riemekasten G, Humrich JY.

Scand J Rheumatol. 2019 Sep 17:1-5. doi: 10.1080/03009742.2019.1641616. [Epub ahead of print]

PMID:
31526060
3.

Evaluation of retinal microvascular perfusion in systemic sclerosis: a case-control study.

Rothe M, Rommel F, Klapa S, Humrich JY, Nieberding R, Lange T, Sochurek JAM, Plöttner P, Grisanti S, Riemekasten G, Ranjbar M.

Ann Rheum Dis. 2019 Jun;78(6):857-858. doi: 10.1136/annrheumdis-2018-214541. Epub 2019 Jan 3. No abstract available.

PMID:
30606740
4.

Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus.

Humrich JY, Riemekasten G.

Curr Opin Rheumatol. 2019 Mar;31(2):208-212. doi: 10.1097/BOR.0000000000000575.

PMID:
30562181
5.

GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis.

Cabral-Marques O, Marques A, Giil LM, De Vito R, Rademacher J, Günther J, Lange T, Humrich JY, Klapa S, Schinke S, Schimke LF, Marschner G, Pitann S, Adler S, Dechend R, Müller DN, Braicu I, Sehouli J, Schulze-Forster K, Trippel T, Scheibenbogen C, Staff A, Mertens PR, Löbel M, Mastroianni J, Plattfaut C, Gieseler F, Dragun D, Engelhardt BE, Fernandez-Cabezudo MJ, Ochs HD, Al-Ramadi BK, Lamprecht P, Mueller A, Heidecke H, Riemekasten G.

Nat Commun. 2018 Dec 6;9(1):5224. doi: 10.1038/s41467-018-07598-9.

6.

Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides.

Lamprecht P, Kerstein A, Klapa S, Schinke S, Karsten CM, Yu X, Ehlers M, Epplen JT, Holl-Ulrich K, Wiech T, Kalies K, Lange T, Laudien M, Laskay T, Gemoll T, Schumacher U, Ullrich S, Busch H, Ibrahim S, Fischer N, Hasselbacher K, Pries R, Petersen F, Weppner G, Manz R, Humrich JY, Nieberding R, Riemekasten G, Müller A.

Front Immunol. 2018 Apr 9;9:680. doi: 10.3389/fimmu.2018.00680. eCollection 2018. Review.

7.

Detection of anti-neutrophil cytoplasmic and antinuclear autoantibodies favouring misdiagnoses in 5 cases of Erdheim-Chester disease.

Özden F, Schinke S, Thorns C, Eckey T, Dalhoff K, Münte TF, Tronnier V, Humrich JY, Riemekasten G, Lamprecht P.

Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):176. Epub 2018 Apr 10. No abstract available.

PMID:
29652657
8.

Diagnosis of deficiency of adenosine deaminase 2 with early onset polyarteritis nodosa in an adult patient with a novel compound heterozygous CECR1 mutation.

Lamprecht P, Humrich JY, Diebold I, Riemekasten G.

Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):177. Epub 2018 Mar 15. No abstract available.

9.

Low-dose IL-2 therapy - a complex scenario that remains to be further explored.

Humrich JY, Riemekasten G.

Nat Rev Rheumatol. 2017 Jun;13(6):386. doi: 10.1038/nrrheum.2017.71. Epub 2017 May 11. No abstract available.

PMID:
28490788
10.

Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE.

Humrich JY, Riemekasten G.

Nat Rev Rheumatol. 2016 Dec;12(12):695-696. doi: 10.1038/nrrheum.2016.173. Epub 2016 Oct 20. No abstract available.

PMID:
27761021
11.

Restoring regulation - IL-2 therapy in systemic lupus erythematosus.

Humrich JY, Riemekasten G.

Expert Rev Clin Immunol. 2016 Nov;12(11):1153-1160. Epub 2016 Jun 23. Review.

PMID:
27283871
12.

Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages.

Klocke J, Kopetschke K, Grießbach AS, Langhans V, Humrich JY, Biesen R, Dragun D, Radbruch A, Burmester GR, Riemekasten G, Enghard P.

Eur J Immunol. 2017 Jan;47(1):180-192. doi: 10.1002/eji.201646387. Epub 2016 Nov 21.

13.

[IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].

Humrich JY, Riemekasten G.

Z Rheumatol. 2016 Jun;75(5):490-2. doi: 10.1007/s00393-016-0129-8. German. No abstract available.

PMID:
27250490
14.

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G, Humrich JY.

Ann Rheum Dis. 2016 Jul;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776. Epub 2015 Aug 31.

PMID:
26324847
15.

The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers.

Kopetschke K, Klocke J, Grießbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, Riemekasten G.

Arthritis Res Ther. 2015 Apr 3;17:94. doi: 10.1186/s13075-015-0600-y.

16.

[Regulatory T cells and rheumatic diseases].

Humrich JY, Kamradt T, Riemekasten G.

Z Rheumatol. 2015 Feb;74(1):26-32. doi: 10.1007/s00393-014-1446-4. Review. German.

PMID:
25676125
17.

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, Riemekasten G.

Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21. No abstract available.

PMID:
25609413
18.

Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response.

Enghard P, Rieder C, Kopetschke K, Klocke JR, Undeutsch R, Biesen R, Dragun D, Gollasch M, Schneider U, Aupperle K, Humrich JY, Hiepe F, Backhaus M, Radbruch AH, Burmester GR, Riemekasten G.

Ann Rheum Dis. 2014 Jan;73(1):277-83. doi: 10.1136/annrheumdis-2012-202784. Epub 2013 Mar 8.

PMID:
23475982
19.

CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.

Weigert O, von Spee C, Undeutsch R, Kloke L, Humrich JY, Riemekasten G.

Arthritis Res Ther. 2013 Feb 27;15(1):R35. doi: 10.1186/ar4188.

20.

CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.

Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA.

Arthritis Rheum. 2012 Apr;64(4):1237-46. doi: 10.1002/art.33424. Epub 2011 Oct 17.

21.

Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus.

Engler JB, Undeutsch R, Kloke L, Rosenberger S, Backhaus M, Schneider U, Egerer K, Dragun D, Hofmann J, Huscher D, Burmester GR, Humrich JY, Enghard P, Riemekasten G.

Ann Rheum Dis. 2011 Dec;70(12):2176-83. doi: 10.1136/ard.2011.153619. Epub 2011 Sep 16.

PMID:
21926188
22.

The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study.

Becker MO, Brückner C, Scherer HU, Wassermann N, Humrich JY, Hanitsch LG, Schneider U, Kawald A, Hanke K, Burmester GR, Riemekasten G.

Ann Rheum Dis. 2011 Jul;70(7):1340-1. doi: 10.1136/ard.2010.137935. Epub 2010 Nov 10. No abstract available.

PMID:
21068100
23.

Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development.

Enghard P, Humrich JY, Chu VT, Grussie E, Hiepe F, Burmester GR, Radbruch A, Berek C, Riemekasten G.

Eur J Immunol. 2010 Jun;40(6):1809-18. doi: 10.1002/eji.200940050.

24.

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.

Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, Kloke L, Heimann J, Gaber T, Brandenburg S, Scheffold A, Huehn J, Radbruch A, Burmester GR, Riemekasten G.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):204-9. doi: 10.1073/pnas.0903158107. Epub 2009 Dec 14.

25.

CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients.

Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A, Manz R, Hiepe F, Radbruch A, Burmester GR, Riemekasten G.

Arthritis Rheum. 2009 Jan;60(1):199-206. doi: 10.1002/art.24136.

26.

Autoregulation of Th1-mediated inflammation by twist1.

Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, Eulenburg K, Kreher S, Koeck J, Baumgrass R, Bonhagen K, Kamradt T, Enghard P, Humrich JY, Rutz S, Schulze-Topphoff U, Aktas O, Bartfeld S, Radbruch H, Hegazy AN, Löhning M, Baumgart DC, Duchmann R, Rudwaleit M, Häupl T, Gitelman I, Krenn V, Gruen J, Sieper J, Zeitz M, Wiedenmann B, Zipp F, Hamann A, Janitz M, Scheffold A, Burmester GR, Chang HD, Radbruch A.

J Exp Med. 2008 Aug 4;205(8):1889-901. doi: 10.1084/jem.20072468. Epub 2008 Jul 28.

27.

Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells.

Humrich JY, Thumann P, Greiner S, Humrich JH, Averbeck M, Schwank C, Kämpgen E, Schuler G, Jenne L.

Eur J Immunol. 2007 Apr;37(4):954-65.

29.

Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration.

Humrich JY, Humrich JH, Averbeck M, Thumann P, Termeer C, Kämpgen E, Schuler G, Jenne L.

Immunology. 2006 Feb;117(2):238-47.

Supplemental Content

Loading ...
Support Center